Academic Journal
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases
| العنوان: | Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases |
|---|---|
| المساهمون: | Won-Woo Seo, Seung In Seo, Yerim Kim, Jong Jin Yoo, Woon Geon Shin, Jinseob Kim, Seng Chan You, Rae Woong Park, Young Min Park, Kyung-Jin Kim, Sang Youl Rhee, Meeyoung Park, Eun-Sun Jin, Sung Eun Kim, You, Seng Chan |
| بيانات النشر: | BioMed Central |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Atorvastatin / adverse effects, Cohort Studies, Diabetes Mellitus* / diagnosis, Diabetes Mellitus* / drug therapy, Diabetes Mellitus* / epidemiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects, Multicenter Studies as Topic, Quinolines, Retrospective Studies, Rosuvastatin Calcium / adverse effects, Common data model, Diabetes mellitus, Pitavastatin, Statin |
| الوصف: | Background: Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin or rosuvastatin using reliable, large-scale data. Methods: Data of electronic health records from ten hospitals converted to the Observational Medical Outcomes Partnership Common Data Model (n = 14,605,368 patients) were used to identify new users of pitavastatin, atorvastatin, or rosuvastatin (atorvastatin + rosuvastatin) for ≥ 180 days without a previous history of diabetes or HbA1c level ≥ 5.7%. We conducted a cohort study using Cox regression analysis to examine the hazard ratio (HR) of NODM after propensity score matching (PSM) and then performed an aggregate meta-analysis of the HR. Results: After 1:2 PSM, 10,238 new pitavastatin users (15,998 person-years of follow-up) and 18,605 atorvastatin + rosuvastatin users (33,477 person-years of follow-up) were pooled from 10 databases. The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosuvastatin (HR 0.72; 95% CI 0.59-0.87). In sub-analysis, pitavastatin was associated with a lower risk of NODM than atorvastatin or rosuvastatin after 1:1 PSM (HR 0.69; CI 0.54-0.88 and HR 0.74; CI 0.55-0.99, respectively). A consistently low risk of NODM in pitavastatin users was observed when compared with low-to-moderate-intensity atorvastatin + rosuvastatin users (HR 0.78; CI 0.62-0.98). Conclusions: In this retrospective, multicenter active-comparator, new-user, cohort study, pitavastatin reduced the risk of NODM compared with atorvastatin or rosuvastatin. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1475-2840 |
| Relation: | CARDIOVASCULAR DIABETOLOGY; J00460; OAK-2022-06052; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191415; T202203417; CARDIOVASCULAR DIABETOLOGY, Vol.21(1) : 82, 2022-05 |
| DOI: | 10.1186/s12933-022-01524-6 |
| الاتاحة: | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191415 https://doi.org/10.1186/s12933-022-01524-6 |
| Rights: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.2341452E |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14752840 |
|---|---|
| DOI: | 10.1186/s12933-022-01524-6 |